In ALL, BET inhibitors have shown efficacy in arresting growth of MLL-AF4+ leukaemic cells and in combination with imatinib in NUP214-ABL1/TLX3-expressing T-ALL cells [125,126]. Here, KMT2A is linked to acute lymphoblastic leukemia.